Vyxeos® (daunorubicin and cytarabine) – Expanded indication
March 30, 2021 - Jazz Pharmaceuticals announced the FDA approval of Vyxeos (daunorubicin and cytarabine), for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Top